Subscribe to RSS
DOI: 10.1055/s-2008-1027605
© Georg Thieme Verlag KG Stuttgart · New York
Kombinierte intravitreale Therapie zur Behandlung der altersbedingten Makuladegeneration
Combined Intravitreal Therapy for Age-Related Macular DiseasePublication History
Eingegangen: 4.4.2008
Angenommen: 27.5.2008
Publication Date:
15 December 2008 (online)

Zusammenfassung
Seit Einführung der intravitrealen Anti-VEGF-Monotherapie konnte bei einem signifikanten Teil der Patienten mit feuchter altersbedingter Makuladegeneration (AMD) der Visus stabilisiert bzw. verbessert werden. Es wird jedoch zunehmend über Sicherheit, Effektivität und ökonomische Aspekte der verschiedenen Konzepte therapeutischer Möglichkeiten diskutiert. Im Rahmen einer prospektiven Fallserie wurde 24 bis 36 Stunden nach initialer fotodynamischer Therapie bei 52 Patienten mit choroidealen Neovaskularisationen bei AMD eine intravitreale Kombinationstherapie durchgeführt. Dabei wurde eine intravitreale Eingabe von BSS, Dexamethason und Bevacizumab (= Multiple Therapie) ohne Parazentese mit dem Intrector® durch eine selbstadaptierende 23-Gauge-Kernvitrektomie ermöglicht, da dieser einen doppelläufigen Kanal für Aspiration und Injektion besitzt. Nach 14 Monaten zeigte sich durchschnittlich ein Visusgewinn von 0,18 Snellen Zeilen, mit einer Visusstabilisierung bei 14 / 52 (27 %) und einem Visusgewinn bei 38 / 52 (73 %) der Patienten. Dieses sichere pharmakochirurgische Therapiekonzept führte zu niedrigen intravitrealen Anti-VEGF-Wiederholungsraten 13 / 52 (25 %).
Abstract
Since the introduction of anti-VEGF drugs for the treatmet of CNV in age-related macular degeneration (AMD), visual acuity can be stabilised or improved in a significant number of patients. There is an ongoing debate on the safety, efficiency and economic aspects related to current intravitreal therapeutic concepts. Twenty-four to 36 hours after 80 % low-fluence verteporfin photodynamic therapy (PDT) a combined phrarmacosurgical intravitreal therapy for 52 patients with wet AMD was conducted (multiple therapy). By performing a 23-gauge core vitrectomy with the Intrector®, an intravitreal substitution with BSS, dexamethasone and bevacizumab was achieved via a self-adapting two-channel cannula for aspiration and injection in one probe tip. After 14 months the mean gain in visual acuity (VA) was 0.18 Snellen lines, with VA stabilisation in 14 / 52 (27 %) and VA gain in 38 / 52 (73 %) of the patients. This safe pharmacosurgical regimen indicated a low intravitreal retreatment rate of (13 / 52) 25 %.
Schlüsselwörter
AMD - Kombinationstherapie - Intrector - Anti-VEGF - Multiple Therapie
Key words
AMD - combined therapy - Intrector - anti-VEGF - multiple therapy
Literatur
- 1
Brown D M, Kaiser P K, Michels M. et al .
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
N Engl J Med.
2006;
355
1432-1444
Reference Ris Wihthout Link
- 2
Gragoudas E S, Adamis A P, Cunningham E T. et al .
Pegaptanib for neovascular age-related macular degeneration.
N Engl J Med.
2004;
351
2805-2816
Reference Ris Wihthout Link
- 3
Rosenfeld P J, Brown D M, Heier J S. et al .
Ranibizumab for neovascular age-related macular degeneration.
N Engl J Med.
2006;
355
1419-1431
Reference Ris Wihthout Link
- 4
Spaide R F, Laud Jr. K, Fine H F. et al .
Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related
macular degeneration.
Retina.
2006;
26
383-390
Reference Ris Wihthout Link
- 5 Chatterjee S P, DaCosta J, Adewoyin T. et al .Combined Photodynamic Therapy with Visudyne, Intravitreal Injection of Lucentis and
Dexamethasone, and Oral Minocycline in the Treatment of Neovascular Age-Related Macular
Degeneration. Ft. Lauderdale; Association of Research in Vision and Ophthalmology -ARVO 2008
Reference Ris Wihthout Link
- 6 Tolentino M J, Berger A, Misch D. et al .Decreased Retreatments and Maintained Efficacy With Triple Therapy (Combination Verteporfin
Photodynamic Therapy, Intravitreal Avastin/Lucentis and Intravitreal Dexamethasone
Teatments) for Patients with Exudative Age Related Macular Degeneration. Ft. Lauderdale; Association of Research in Vision and Ophthalmology – ARVO 2008
Reference Ris Wihthout Link
- 7
Grossniklaus H E, Ling J X, Wallace T M. et al .
Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal
neovascularization.
Mol Vis.
2002;
8
119-126
Reference Ris Wihthout Link
- 8
Penfold P L, Liew S C, Madigan M C. et al .
Modulation of major histocompatibility complex class II expression in retinas with
age-related macular degeneration.
Invest Ophthalmol Vis Sci.
1997;
38
2125-2133
Reference Ris Wihthout Link
- 9
Penfold P L, Madigan M C, Gillies M C. et al .
Immunological and aetiological aspects of macular degeneration.
Prog Retin Eye Res.
2001;
20
385-414
Reference Ris Wihthout Link
- 10
Dvorak H F, Nagy J A, Feng D. et al .
Vascular permeability factor/vascular endothelial growth factor and the significance
of microvascular hyperpermeability in angiogenesis.
Curr Top Microbiol Immunol.
1999;
237
97-132
Reference Ris Wihthout Link
- 11
Espinosa-Heidmann D G, Reinoso M A, Pina Y. et al .
Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived
from bone marrow precursors in experimental choroidal neovascularization.
Exp Eye Res.
2005;
80
369-378
Reference Ris Wihthout Link
- 12
Grossniklaus H E, Green W R.
Choroidal neovascularization.
Am J Ophthalmol.
2004;
137
496-503
Reference Ris Wihthout Link
- 13
Tsutsumi-Miyahara C, Sonoda K H, Egashira K. et al .
The relative contributions of each subset of ocular infiltrated cells in experimental
choroidal neovascularisation.
Br J Ophthalmol.
2004;
88
1217-1222
Reference Ris Wihthout Link
- 14
Pugh C W, Ratcliffe P J.
Regulation of angiogenesis by hypoxia: role of the HIF system.
Nat Med.
2003;
9
677-684
Reference Ris Wihthout Link
- 15
Shweiki D, Itin A, Soffer D. et al .
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated
angiogenesis.
Nature.
1992;
359
843-845
Reference Ris Wihthout Link
- 16
Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C. et al .
Influence of photodynamic therapy on expression of vascular endothelial growth factor
(VEGF), VEGF receptor 3, and pigment epithelium-derived factor.
Invest Ophthalmol Vis Sci.
2003;
44
4473-4480
Reference Ris Wihthout Link
- 17
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular
degeneration with verteporfin: one-year results of 2 randomized clinical trials –
TAP report. Treatment of age-related macular degeneration with photodynamic therapy
(TAP) Study Group.
Arch Ophthalmol.
1999;
117
1329-1345
Reference Ris Wihthout Link
- 18
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular
degeneration: two-year results of a randomized clinical trial including lesions with
occult with no classic choroidal neovascularization – verteporfin in photodynamic
therapy report 2.
Am J Ophthalmol.
2001;
131
541-560
Reference Ris Wihthout Link
- 19
Schmidt-Erfurth U M, Pruente C.
Management of neovascular age-related macular degeneration.
Prog Retin Eye Res.
2007;
26
437-451
Reference Ris Wihthout Link
- 20
Chen C Y, Wong T Y, Heriot W J.
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration:
a short-term study.
Am J Ophthalmol.
2007;
143
510-512
Reference Ris Wihthout Link
- 21
D’Amico D J, Masonson H N, Patel M. et al .
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety
results of the two prospective, multicenter, controlled clinical trials.
Ophthalmology.
2006;
113
992-1001 e1006
Reference Ris Wihthout Link
- 22 Mieler W. PIER: 1 Year FA/OCT Results in a Study of Ranibizumab (Lucentis®) for Choroidal Neovascularisation
(CNV) due to Age related Macular Degeneration (AMD). 24th Annual meeting of the American Society of Retina Specialists and 6th annual meeting
of the European Vitreoretinal Society Cannes, France; 2006
Reference Ris Wihthout Link
- 23
Fung A E, Lalwani G A, Rosenfeld P J. et al .
An optical coherence tomography-guided, variable dosing regimen with intravitreal
ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Am J Ophthalmol.
2007;
143
566-583
Reference Ris Wihthout Link
- 24
Danis R P, Ciulla T A, Pratt L M. et al .
Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.
Retina.
2000;
20
244-250
Reference Ris Wihthout Link
- 25
Gillies M C, Simpson J M, Billson F A. et al .
Safety of an intravitreal injection of triamcinolone: results from a randomized clinical
trial.
Arch Ophthalmol.
2004;
122
336-340
Reference Ris Wihthout Link
- 26
Jonas J B, Akkoyun I, Budde W M. et al .
Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.
Arch Ophthalmol.
2004;
122
218-222
Reference Ris Wihthout Link
- 27
Lee J, Freeman W R, Azen S P. et al .
Prospective, randomized clinical trial of intravitreal triamcinolone treatment of
neovascular age-related macular degeneration: one-year results.
Retina.
2007;
27
1205-1213
Reference Ris Wihthout Link
- 28
Augustin A J, Schmidt-Erfurth U.
Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal
neovascularization due to age-related macular degeneration.
Ophthalmology.
2006;
113
14-22
Reference Ris Wihthout Link
- 29
Ruiz-Moreno J M, Montero J A, Barile S. et al .
Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related
macular degeneration: 1-year outcome.
Retina.
2006;
26
602-612
Reference Ris Wihthout Link
- 30
Spaide R F, Sorenson J, Maranan L.
Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone
acetonide for choroidal neovascularization.
Ophthalmology.
2005;
112
301-304
Reference Ris Wihthout Link
- 31
Tatar O, Adam A, Shinoda K. et al .
Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin
photodynamic therapy.
Am J Ophthalmol.
2006;
142
95-104
Reference Ris Wihthout Link
- 32
Heier J S, Boyer D S, Ciulla T A. et al .
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related
macular degeneration: year 1 results of the FOCUS Study.
Arch Ophthalmol.
2006;
124
1532-1542
Reference Ris Wihthout Link
- 33
Costa R A, Jorge R, Calucci D. et al .
Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy
for choroidal neovascularization associated with age-related macular degeneration
(IBeVe Study).
Graefes Arch Clin Exp Ophthalmol.
2007;
245
1273-1280
Reference Ris Wihthout Link
- 34
Dhalla M S, Shah G K, Blinder K J. et al .
Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal
neovascularization in age-related macular degeneration.
Retina.
2006;
26
988-993
Reference Ris Wihthout Link
- 35
Lazic R, Gabric N.
Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization
due to age-related macular degeneration.
Ophthalmology.
2007;
114
1179-1185
Reference Ris Wihthout Link
- 36
Augustin A J, Puls S, Offermann I.
Triple therapy for choroidal neovascularization due to age-related macular degeneration:
verteporfin PDT, bevacizumab, and dexamethasone.
Retina.
2007;
27
133-140
Reference Ris Wihthout Link
- 37
Liggett P E, Colina J, Chaudhry N A. et al .
Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib
sodium for choroidal neovascularization.
Am J Ophthalmol.
2006;
142
1072-1074
Reference Ris Wihthout Link
- 38
Ahmadieh H, Taei R, Soheilian M. et al .
Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone
for neovascular age-related macular degeneration.
BMC Ophthalmol.
2007;
7
10
Reference Ris Wihthout Link
- 39
Aiello L P, Avery R L, Arrigg P G. et al .
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy
and other retinal disorders.
N Engl J Med.
1994;
331
1480-1487
Reference Ris Wihthout Link
- 40
Ahmed J, Braun R D, Dunn R . et al .
Oxygen distribution in the macaque retina.
Invest Ophthalmol Vis Sci.
1993;
34
516-521
Reference Ris Wihthout Link
- 41 Holekamp N M, Shui Y B, Beebe Jr. D. Vitreous consumes oxygen: implications for vitrectomy surgery. Aspen Vitrectomy meeting 2006
Reference Ris Wihthout Link
- 42
Stefansson E, Landers 3 rd M B.
How does vitrectomy affect diabetic macular edema?.
Am J Ophthalmol.
2006;
141
984-985
Reference Ris Wihthout Link
- 43
Stefansson E, Loftsson T.
The Stokes-Einstein equation and the physiological effects of vitreous surgery.
Acta Ophthalmol Scand.
2006;
84
718-719
Reference Ris Wihthout Link
- 44
Saito Y, Lewis J M, Park I. et al .
Nonvitrectomizing vitreous surgery: a strategy to prevent postoperative nuclear sclerosis.
Ophthalmology.
1999;
106
1541-1545
Reference Ris Wihthout Link
- 45
Sawa M, Saito Y, Hayashi A. et al .
Assessment of nuclear sclerosis after nonvitrectomizing vitreous surgery.
Am J Ophthalmol.
2001;
132
356-362
Reference Ris Wihthout Link
- 46 Holekamp N M. How the Vitreous consumes oxygen. Retina Subspecialty Day of the Annual American Academy of Ophthalmology New Orleans; 2007
Reference Ris Wihthout Link
- 47
Krebs I, Brannath W, Glittenberg C. et al .
Posterior vitreomacular adhesion: a potential risk factor for exudative age-related
macular degeneration?.
Am J Ophthalmol.
2007;
144
741-746
Reference Ris Wihthout Link
Prof. Frank Koch
Abteilung für Netzhaut und Glaskörperchirurgie, Zentrum für Augenheilkunde, Klinikum
der Johann Wolfgang Goethe Universität Frankfurt/Main
Theodor-Stern Kai 7
60590 Frankfurt/Main
Phone: ++ 49/69/63 01 56 49
Fax: ++ 49/69/63 01 56 21
Email: fkoch1@mac1.com